Авторы работы сравнили защитную эффективность разных типов вакцин от ковида по данным вакцинации и заболеваемости в штате и пришли к выводу, что эффективность защиты от болезни довольно высокая, для всех вакцин, хотя и несколько спадает со временем после прививки, особенно среди тех, кому более 65. От госпитализации защита выше (более 86%), чем от заражения (70-85%). Но в основном защита терялась, потому что пришел новый штамм.
Так же авторы отметили, что после того как СДС снова вернуло рекомендацию ходить в масках, заболеваемость и госпитализация среди привитых- снизились (по сравнению с предыдущим периодом, когда "разрешили" не соблюдать меры, май-июнь)
Among a total of 8,834,604 adults in this analysis, 5,787,817 (65.5%) were fully-vaccinated.
Among those fully-vaccinated, 48.6% received Pfizer, 41.5% Moderna, and 10.0% Janssen.
During follow-up, fully-vaccinated persons experienced a total of 38,778 cases and 2,363 hospitalizations
and unvaccinated persons had 116,314 cases and 38,778 hospitalizations.
For persons 18-49 years, VE for Pfizer-BioNTech declined 27.8% from 93.6% during the May 1 to July 10 weeks, and increased 3.2% by the August 28 week. Similarly, Moderna VE decreased 19.3% from 96.5%, then increased 1.3%. For Janssen, VE decreased 37.7% from 89.4%, then increased 18.5% , with less stable estimates. Differences within product between time cohorts were smaller over time. At the end of observation, VE ranged 4.2% across time cohorts for Pfizer, 11.0% for Moderna, and 4.9% for Janssen.
For persons 50-64 years, VE for Pfizer-BioNTech decreased 23.8% from 95.3% during May 1 to July 10, and increased 4.7% by August 28. Similarly, Moderna VE decreased 11.6% from 97.4%, then decreased 2.9%. For Janssen, VE decreased 14.2% from 86.8%, then increased 3.4% . At the end of observation, VE ranged 4.0% across time cohorts for Pfizer, 11.1% for Moderna, and 8.0% for Janssen, with a gradient of lower VE point estimates for earlier-vaccinated cohorts.
Among persons ≥65 years, VE for Pfizer-BioNTech decreased 12.7% from 91.9% during May 1 to July 10, and decreased 1.4% by August 28. Likewise, Moderna VE decreased 9.0% from 96.2%, then decreased 2.9%. For Janssen, VE decreased 2.4% from 81.7%, then decreased 8.4%.
At the end of observation, VE ranged 3.2% across time cohorts for Pfizer, 6.7% for Moderna, and 6.7% for Janssen, with lower VE point estimates for earlier-vaccinated cohorts. By analyzing large cohorts of NYS residents, we observed substantial declines in VE for COVID-19 cases from May to August 2021. These declines occurred simultaneously across age, product, and time-cohort, with the largest declines seen for Pfizer-BioNTech recipients. VE declines by time-cohort were not offset in calendar time by approximately one-month, which would have suggestedimmunologic waning. However,trends in VE were highly inversely-correlated with increasing Delta variant prevalence and plateaued for persons 18-64 years during the period in which Delta exceeded 85%. VE continued to modestly decline for persons ≥65 years. In contrast, VE for hospitalizations remained high, with lower levels for persons ≥65 years and those receiving Janssen, and modest declines over time within-6%,limited to Pfizer-BioNTech and Moderna recipients ≥65 years